163 related articles for article (PubMed ID: 35902886)
1. Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer.
Hogg SJ; Motorna O; Kearney CJ; Derrick EB; House IG; Todorovski I; Kelly MJ; Zethoven M; Bromberg KD; Lai A; Beavis PA; Shortt J; Johnstone RW; Vervoort SJ
Clin Epigenetics; 2022 Jul; 14(1):96. PubMed ID: 35902886
[TBL] [Abstract][Full Text] [Related]
2. Differential contribution of p300 and CBP to regulatory element acetylation in mESCs.
Martire S; Nguyen J; Sundaresan A; Banaszynski LA
BMC Mol Cell Biol; 2020 Jul; 21(1):55. PubMed ID: 32690000
[TBL] [Abstract][Full Text] [Related]
3. Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.
Hogg SJ; Motorna O; Cluse LA; Johanson TM; Coughlan HD; Raviram R; Myers RM; Costacurta M; Todorovski I; Pijpers L; Bjelosevic S; Williams T; Huskins SN; Kearney CJ; Devlin JR; Fan Z; Jabbari JS; Martin BP; Fareh M; Kelly MJ; Dupéré-Richer D; Sandow JJ; Feran B; Knight D; Khong T; Spencer A; Harrison SJ; Gregory G; Wickramasinghe VO; Webb AI; Taberlay PC; Bromberg KD; Lai A; Papenfuss AT; Smyth GK; Allan RS; Licht JD; Landau DA; Abdel-Wahab O; Shortt J; Vervoort SJ; Johnstone RW
Mol Cell; 2021 May; 81(10):2183-2200.e13. PubMed ID: 34019788
[TBL] [Abstract][Full Text] [Related]
4. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
[TBL] [Abstract][Full Text] [Related]
5. Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release.
Narita T; Ito S; Higashijima Y; Chu WK; Neumann K; Walter J; Satpathy S; Liebner T; Hamilton WB; Maskey E; Prus G; Shibata M; Iesmantavicius V; Brickman JM; Anastassiadis K; Koseki H; Choudhary C
Mol Cell; 2021 May; 81(10):2166-2182.e6. PubMed ID: 33765415
[TBL] [Abstract][Full Text] [Related]
6. RNA Binding to CBP Stimulates Histone Acetylation and Transcription.
Bose DA; Donahue G; Reinberg D; Shiekhattar R; Bonasio R; Berger SL
Cell; 2017 Jan; 168(1-2):135-149.e22. PubMed ID: 28086087
[TBL] [Abstract][Full Text] [Related]
7. Histone Acetyltransferases p300 and CBP Coordinate Distinct Chromatin Remodeling Programs in Vascular Smooth Muscle Plasticity.
Chakraborty R; Ostriker AC; Xie Y; Dave JM; Gamez-Mendez A; Chatterjee P; Abu Y; Valentine J; Lezon-Geyda K; Greif DM; Schulz VP; Gallagher PG; Sessa WC; Hwa J; Martin KA
Circulation; 2022 Jun; 145(23):1720-1737. PubMed ID: 35502657
[TBL] [Abstract][Full Text] [Related]
8. Frequent interferon regulatory factor 1 (IRF1) binding at remote elements without histone modification.
Abou El Hassan M; Huang K; Xu Z; Yu T; Bremner R
J Biol Chem; 2018 Jun; 293(26):10353-10362. PubMed ID: 29748386
[TBL] [Abstract][Full Text] [Related]
9. A quinazoline-based bromodomain inhibitor, CN210, ameliorates indomethacin-induced ileitis in mice by inhibiting inflammatory cytokine expression.
Noguchi T; Hidaka K; Kobayashi S; Matsumoto K; Yoshioka M; Hu X; Maloney DJ; Yang SM; Kato S
Drug Dev Res; 2021 Dec; 82(8):1235-1246. PubMed ID: 34075610
[TBL] [Abstract][Full Text] [Related]
10. Individual functions of the histone acetyl transferases CBP and p300 in regulating the inflammatory response of synovial fibroblasts.
Krošel M; Gabathuler M; Maciukiewicz M; Moser L; Lee GI; Marks M; Tomšič M; Distler O; Ospelt C; Klein K
J Autoimmun; 2021 Sep; 123():102709. PubMed ID: 34304080
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of interleukin 1-induced matrix metalloproteinase 13 expression in human chondrocytes by interferon gamma.
Ahmad R; Qureshi HY; El Mabrouk M; Sylvester J; Ahmad M; Zafarullah M
Ann Rheum Dis; 2007 Jun; 66(6):782-9. PubMed ID: 17179173
[TBL] [Abstract][Full Text] [Related]
12. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation.
Raisner R; Kharbanda S; Jin L; Jeng E; Chan E; Merchant M; Haverty PM; Bainer R; Cheung T; Arnott D; Flynn EM; Romero FA; Magnuson S; Gascoigne KE
Cell Rep; 2018 Aug; 24(7):1722-1729. PubMed ID: 30110629
[TBL] [Abstract][Full Text] [Related]
13. BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner in human monocytes.
Chan CH; Fang C; Yarilina A; Prinjha RK; Qiao Y; Ivashkiv LB
Eur J Immunol; 2015 Jan; 45(1):287-297. PubMed ID: 25345375
[TBL] [Abstract][Full Text] [Related]
14. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.
Zucconi BE; Luef B; Xu W; Henry RA; Nodelman IM; Bowman GD; Andrews AJ; Cole PA
Biochemistry; 2016 Jul; 55(27):3727-34. PubMed ID: 27332697
[TBL] [Abstract][Full Text] [Related]
15. IFNγ Induces DNA Methylation-Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer.
Bardhan K; Paschall AV; Yang D; Chen MR; Simon PS; Bhutia YD; Martin PM; Thangaraju M; Browning DD; Ganapathy V; Heaton CM; Gu K; Lee JR; Liu K
Cancer Immunol Res; 2015 Jul; 3(7):795-805. PubMed ID: 25735954
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
17. P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1), paired-like homeoprotein, through acetylation of the conserved lysine residue adjacent to the homeodomain.
Iioka T; Furukawa K; Yamaguchi A; Shindo H; Yamashita S; Tsukazaki T
J Bone Miner Res; 2003 Aug; 18(8):1419-29. PubMed ID: 12929931
[TBL] [Abstract][Full Text] [Related]
18. Distinct roles for CBP and p300 on the RA-mediated expression of the meiosis commitment gene Stra8 in mouse embryonic stem cells.
Chen W; Jia W; Wang K; Si X; Zhu S; Duan T; Kang J
PLoS One; 2013; 8(6):e66076. PubMed ID: 23785470
[TBL] [Abstract][Full Text] [Related]
19. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
20. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J; Chen Z; Qiao Y; Tien JC; Young E; Mannan R; Mahapatra S; He T; Eyunni S; Zhang Y; Zheng Y; Su F; Cao X; Wang R; Cheng Y; Seri R; George J; Shahine M; Miner SJ; Vaishampayan U; Wang M; Wang S; Parolia A; Chinnaiyan AM
bioRxiv; 2024 May; ():. PubMed ID: 38586029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
